RXRA
Retinoic acid receptor RXR-alpha
As of the edition of 20 October 2026, RXRA (retinoic acid receptor RXR-alpha, UniProt P19793) has 7 drugs tested at it and 7 companies on the list, 2 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P19793
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 110
- Disease areas
- Cancer; Skin and connective tissue; Immune system; Blood and lymph; Lungs and airways; Infections; Urinary and reproductive; Digestive system
- Registered trials of its drugs
- 78
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Stopped | 2 |
| Withdrawn from market | 1 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Bexarotene | Marketed | Phase 4 | none listed |
| Acitretin | Marketed | Phase 4 | none listed |
| Alitretinoin | Marketed | Phase 3 | none listed |
| IRX-4204 | Stopped | Phase 2 | none listed |
| SDX-101 | Stopped | Phase 2 | none listed |
| Danthron | Marketed | No phase stated | none listed |
| Etretinate | Withdrawn from market | No phase stated | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 3 |
| Undetermined | 2 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| Bausch Health | Route B |
| H.A.C. Pharma | Route B |
| Io Therapeutics | Route A |
The other 4 companies at RXRA
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at RXRA, ranked, with the facts behind eachRequest access. Nothing is shown until you do.